Ann: App 4E / Full Year Statutory Accounts, page-30

TDA,

Quiet a few positive developments and announcements to look forward to in the near-term:

1. CPT-1 Code descriptor - imminent.

2 Medicare/Medicaid - Reimbursement rates to GPs: November

3. Private Health Insurers - Update on 200 million lives covered by private sector health plans. Expected to follow Medicare's lead. Coverage decision pending following internal reviews from private insurers.

4. Updates on increased use of SphymgaCor in pharmaceutical trials. Diversification of pharmaceutical business, increasing number of therapeutic areas in which they conduct trials.

This includes three new companies engaged with - expect contracts over the next year. Also re-engaged with another company for an important trial in gout - trial commenced, results pending.

5. Oscar2 with SphymgaCor Inside - FDA approval in November, if not before - CEO's report in recently filed 4E actually says, "we expect to receive FDA clearance to sell this product in the USA within the next two months."

6. Oscar2 is the first product to contain SphymgaCor technology in a codified chip, allowing further co-branding and partnership opportunities with OEMs'.

Sales into new markets and disease states.

7. Successful clinical study using SphymgaCor in cardiac pacemaker implantation. Commercialisation discussions underway with two potential partners.

Also the Cerebral Vascular and Intensive Care market - working with Macquarie University on IP, parallel investigation with European Device Company.

8. New initiatives in China and Korea are beginning to accelerate market penetration.

Also in advanced negotiation with a potential distribution partner in Japan, and anticipate agreement with a major partner before end of 2015.

9. US$20 million potential sales currently under management. Atcor retains a strong pipeline of potential new business and has not lost any pharmaceutical contracts to competitors.

10. Commercial scale-up commenced to meet anticipated demand from US$1 billion clinical market following CPT-1 code.

What's not to like, especially at this price